Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective (Q34675820)

3 August 2017

1 reference

title

Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective (English)

1 reference

3 August 2017

0 references

2

0 references

Carolyn F. Deacon

object named as

Carolyn F Deacon

series ordinal

1

0 references

language of work or name

English

0 references

publication date

1 May 2002

1 reference

Biochemical and Biophysical Research Communications

3 August 2017

1 reference

3 August 2017

294

1 reference

3 August 2017

1

1 reference

3 August 2017

1-4

1 reference

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Hamster preproglucagon contains the sequence of glucagon and two related peptides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Renal catabolism of truncated glucagon-like peptide 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel [...]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2900359-5

10.1016/S0006-291X(02)00359-5

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

12054731